InsidersTradesSigma
Track the 삼성바이오로직스 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 삼성바이오로직스 has logged 119 public disclosures. Market capitalisation: €68,880.9bn. The latest transaction was disclosed on 20 May 2026 (Purchase). Among the most active insiders: 이재선. All data is free.
117
Insider Decl.
n/a
Thresholds
n/a
36 ops.
Buy Volume
n/a
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 삼성바이오로직스 Strong Buy (bullish), based on 25 analysts. Average price target: ₩1,975,520.
12Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,510 of 29,056 companies
60.2
score / 100
Value36
Quality84
FCF yld1.1%
Earn yld2.6%
EV/EBITDA25.5x
ROE19%
Gross mgn55%
Net mgn39%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 May 2026
Declarations119 total
Other
Other
25 of 119 declarations
Acerca de 삼성바이오로직스
Samsung Biologics es una empresa surcoreana especializada en la fabricación de productos biofarmacéuticos. Cotiza en la Bolsa de Corea, XKRX.